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The impact of estrogens on the viability of cardiovascular system and their ability to regulate platelet function is still an open and debated
question. We have previously shown that estrogen is able to significantly potentiate the aggregation induced by low doses of thrombin and to
initiate a rapid and reversible signaling pathway mediated by ERβ-directed activation of the tyrosine kinases Src and Pyk2 at the level of the
plasma membrane. Lipid rafts are critical, cholesterol-enriched membrane domains, which play a major role in blood platelet activation processes.
In this work, we investigated the role of lipid rafts in 17β-estradiol signaling in human platelets. We observed that membrane rafts were essential
for both 17β-estradiol-dependent potentiation of platelet aggregation induced by subthreshold concentrations of thrombin and 17β-estradiol-
induced phosphorylation of Src. 17β-estradiol caused the reversible translocation of ERβ to the raft fractions and promoted the rapid and transient
recruitment to, and activation within the membrane raft domains of the tyrosine kinases Src and Pyk2. The raft integrity was essential with this
respect, as these effects of 17β-estradiol were completely inhibited by cholesterol depletion. This paper provides evidence for the first time that
membrane lipid rafts coordinate estrogen signaling in human platelets.
© 2007 Elsevier B.V. All rights reserved.Keywords: Platelets; Lipid rafts; Estrogen1. Introduction
Steroid hormones bind to nuclear receptors and regulate a
number of biological processes, including morphogenesis, cell
proliferation, differentiation, and apoptosis [1,2]. Recently it
has been reported that, in addition to these classical actions,
steroid hormones can also induce rapid, non-genomic effects in
different cell types [3]. These effects include regulation of
adenylyl cyclase, stimulation of p21ras and mitogen-activated
protein kinases, activation of phosphatidylinositol 3-kinase
(PI3-K), and mobilization of Ca2+ from intracellular stores
[4–11]. Estrogens can also affect the cardiovascular system,☆ This work was presented in part at the Annual Meeting of the International
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doi:10.1016/j.bbamcr.2006.12.001although conflicting effects have been reported. In fact, it has
been shown that estrogens can, on one hand, improve vessel
wall viability by acting as a vasodilator and hypotensive agents,
but, on the other hand, they can also increase the thrombotic risk
when used in contraceptive therapy or at acute doses. Sex
steroid hormones have also been shown to affect the platelet
functionality [12–18]. Recently, we have provided evidence that
17β-estradiol (17β-E2) exerts a priming effect on thrombin-
dependent platelet aggregation. Moreover, we have demon-
strated that in human platelets 17β-E2 promotes protein
tyrosine phosphorylation, and orchestrates the assembly of a
signaling complex, which includes the estrogen receptor, Src,
Pyk2, and PI3-K. These events are dependent on the engage-
ment of estrogen receptor beta (ERβ), which is the predomi-
nant estrogen receptor in platelets, and is associated to the
membranes [19].
It is very well known that individual lipids within the plasma
membrane are unequally distributed and form distinct micro-
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regions characterized by amount of glycosphingolipids, satu-
rated phospholipids and cholesterol higher than the rest of
the membrane, and called lipid rafts, have been proposed to play
a role in membrane signaling [20]. Some membrane-associated
signaling proteins, including tyrosine kinases of the Src family,
Gα subunits of heterotrimeric G proteins, endothelial nitric
oxide synthase, and the adaptor protein LAT, have been found
to localize into lipid rafts [21]. Some of these proteins have
a weak affinity for membrane rafts, which, however, may in-
crease upon cell stimulation [22]. At this time, most findings
support the notion that rapid estrogen signaling is mediated by
ER associated with specialized lipid raft domains that serve to
concentrate and provide a matrix for receptors and related
signaling proteins [23–26].
Removal of cholesterol from lipid rafts disorganizes these
structures, and has been shown to alter several cell responses to
extracellular agonists, and to cause, for instance, inhibition of
Ca2+ mobilization following stimulation of T cells [27], reduc-
tion of tyrosine phosphorylation and association with Lyn of
aggregated FcεRI in mast cells [28], and hyperactivation of
ERK in stimulated fibroblasts [29].
Lipid rafts play also a role in platelet signaling [30]. Recent
works have demonstrated that these membrane microdomains
orchestrate the signaling through the collagen platelet receptor
glycoprotein (GP) VI, which is constitutively associated with
the Fc receptor γ-chain (FcRγ-chain). The GPVI–FcRγ-chain
complex is recruited into lipid rafts upon the engagement of
GPVI by its ligand, and this event is essential for the subsequent
phosphorylation of FcRγ-chain [31]. Similarly, the major
platelet adhesion receptor, the GPIb-IX-V, strongly increases
its association with lipid rafts upon stimulation with von
Willebrand Factor [32], and, during platelet spreading,
cholesterol-enriched microdomains accumulate at the extended
tips of the formed filopodia, containing higher amount of c-Src
and the tetraspanning CD63 [33]. Furthermore, it has been
shown that platelet activation and aggregation induced by low
doses of thrombin are dependent on lipid raft integrity [34].
In this work, we have investigated the role of lipid rafts
in 17β-E2-dependent signaling in human platelets. We found
that membrane rafts were essential both for 17β-E2-dependent
potentiation of platelet aggregation induced by subthreshold
concentrations of thrombin, and for 17β-E2-induced phospho-
rylation of Src. We found that ERβ reversibly translocated to
the lipid raft fractions in a hormone-dependent manner, and
promoted the rapid and transient recruitment and activation of
the tyrosine kinases Src and Pyk2 within the membrane raft
domains. In addition, we demonstrated for the first time that
membrane lipid rafts coordinate estrogen signaling in human
platelets.2. Materials and methods
2.1. Materials
Polyclonal antibodies against ERβ and Pyk2, anti-goat horseradish–
peroxidase-conjugated antibody, and a polyclonal antibody against c-Src(SRC2) recognizing the Src family kinases Src (p60), Yes (p62) and Fyn
(p59) were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Polyclonal antibodies against p85-PI3-K and LAT were from Upstate Bio-
technology Inc. (Lake Placid, NY, USA). Polyclonal anti p44/42 MAP Kinase
and phospho-specific polyclonal antibody anti-Pyk2 (Tyr402) were from Cell
Signaling Technology Inc. (Beverly, MA, USA). Goat anti-mouse IgG
horseradish-peroxidase-labeled antibodies, and enhanced chemiluminescence
reagents were from Perkin Elmer Life Science Inc. (Boston, MA, USA) and goat
anti-rabbit IgG horseradish-peroxidase-labeled antibody was from NEN™ Life
Science Products (Brussels, Belgium). Phospho-specific polyclonal antibody
anti-Src kinases (Tyr418), cholera toxin B subunit-peroxidase conjugated, 17β-
E2, methyl-β-cyclodextrin, protease inhibitor cocktail, bovine serum albumin,
phenylmethylsulfonyl fluoride (PMSF) and Na3VO4 were purchased from
Sigma-Aldrich (San Luis, MO, USA). Brij58 was from Pierce (Rochford, IL,
USA). Electrophoresis reagents were from Bio-Rad Laboratories (Hercules, CA,
USA). Hybond-P PVDF transfer membranes and Hyperfilm-ECL were from GE
Healthcare Bio-Sciences AB (Uppsala, Sweden). All other reagents were of
analytical grade.
2.2. Platelet isolation, methyl-β-cyclodextrin treatment and
platelet aggregation
Blood was withdrawn from 20 to 40 years old healthy male volunteers, who
had not taken any drugs for at least 2 weeks before venipuncture, using ACD
(130 mM citric acid, 152 mM sodium citrate, 112 mM glucose), as anti-
coagulant, and platelet-rich plasma was prepared by centrifugation at 180×g for
10 min at 20 °C. For membrane cholesterol depletion, platelet-rich plasma was
incubated with 20 mM methyl-β-cyclodextrin (MβCD) for 30 min at 37 °C.
Platelets were recovered, and washed twice with PIPES buffer (20 mM Pipes,
136 mMNaCl, pH 6.5). Platelet count was adjusted to 3×108 cells/ml in HEPES
buffer containing 2 mM CaCl2, 2 mM MgCl2 and 2 mM glucose. Samples of
platelet suspension (0.4 ml) were pre-warmed at 37 °C in a Chrono-log lumi-
aggregometer, treated with vehicle or with 17β-E2 (100 nM) for 30 s and then
stimulated with low or high (1 U/ml) doses of thrombin. As low dose of
thrombin was considered the concentration of the agonist able to induce normal
shape change but negligible aggregation. Usually it ranged between 0.04 and
0.08 U/ml, depending on the specific reactivity of platelets from different
donors. Platelet aggregation was monitored continuously for at least 5 min as
increase in light transmission.
2.3. Platelet lysis and recovery of membrane lipid rafts
Washed platelets, untreated or treated with MβCD as described above, were
adjusted to a final concentration of 2.5×109 cells/ml in HEPES buffer con-
taining 0.1% glucose. Samples of platelet suspension were treated with vehicle
or with 100 nM 17β-E2 for 30 and 60 s, and then lysed with ice-cold 0.1%
Brij58-containing buffer (0.1% Brij58, 150 mMNaCl, 25 mMMes, pH 6.5, and
2 mM PMSF, 2 mM Na3VO4, 1X protease inhibitor cocktail) or with ice-cold
0.1% Triton X-100-containing buffer (0.1% Triton X-100, 150 mM NaCl,
25 mM Mes, pH 6.5, and 2 mM PMSF, 2 mM Na3VO4, 1X protease inhibitor
cocktail). Lysates were adjusted to 40% sucrose by the addition of an equal
volume of 80% sucrose in Mes-buffered saline (MBS; 25 mMMes, pH 6.5, and
150 mM NaCl, 2 mM PMSF, 2 mM Na3VO4, 1X protease inhibitor cocktail). A
six steps discontinuous gradient of 10–30% sucrose in MBS was formed on the
top of the 40% homogenate in an ultracentrifuge tube. Tubes were centrifuged
at 160,000×g at 4 °C for 16 h. Twelve fractions of equal volumes (1 ml) were
then collected from the top of the tube. Fractions were analyzed by dot blot with
peroxidase conjugated-cholera toxin subunit to identify the fractions enriched
in the GM1 ganglioside. In some experiments aliquots of each fraction were
analyzed by immunoblotting with antibodies to p44/42 ERK and LAT. Raft, and
non-raft (soluble), fractions were typically pooled, and aliquots (200 μl) were
analyzed by immunoblotting.
2.4. Analysis of ERβ localization within the platelet membranes
Aliquots of combined raft fractions and soluble fractions were subjected to
protein precipitation with TCA. One volume of 100% TCA was added to 4
Fig. 2. Platelet lipid rafts play a role in 17β-E2-induced Src kinase activation.
Samples of washed platelets, untreated (NT) or pre-treated with 20 mM MβCD
for 30 min at 37 °C, were incubated with 100 nM 17β-E2 for times ranging from
30 to 180 s, as indicated. Aliquots of each sample containing the same amount of
proteins were simultaneously analyzed by immunoblotting using anti-pSrc-
Tyr418 (top panels) and anti-Src antibodies (lower panels). The immunoblot
analysis shown in the figure is from a representative experiment out of the 4
performed with platelets obtained from different donors.
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were centrifuged at 13,000 rpm for 15 min. The supernatants were carefully
removed, and the pellets were washed twice with 200 μl cold acetone. The
precipitated proteins were then dried by placing tubes in a fumehood for 10 min.
Dried samples were solubilized in 3X Laemmly buffer (70 μl) and analyzed by
immunoblotting with antibodies to ERβ.
2.5. Electrophoresis and Immunoblotting analysis
Samples of washed platelets suspension, pre-treated or not with 20 mM
MβCD for 30 min at 37 °C, were further incubated with 100 nM 17β-E2 for
times ranging from 30 to 180 s. Aliquots of each sample containing the same
amount of proteins were analyzed by immunoblotting using anti-pSrc-Tyr418
and anti-Src antibodies. Aliquots of combined raft fractions and soluble frac-
tions were analyzed by SDS-PAGE on a 10% polyacrylamide gel, transferred to
PVDF membrane, and probed with antibodies specific to Pyk2, Src and p85-
PI3-K. The activation state of Src and Pyk2 was evaluated by phospho-specific
polyclonal antibody anti-Pyk2 (Tyr402) and anti-Src kinases (Tyr418). Chemi-
luminescent signals were detected using the Versadoc Imaging System and
analyzed using Quantity One software (Bio-Rad Laboratories). Only unsatu-
rated images were considered.
3. Results
3.1. Lipid rafts mediate 17β-E2-dependent potentiation of
thrombin-induced platelet aggregation
A growing number of evidence indicates that the
cholesterol-rich membrane regions named lipid rafts, are
implicated in the mechanisms of platelet activation by
physiologic agonists. We first investigated the effect of lipid
rafts disruption by membrane cholesterol depletion on platelet
aggregation caused by high and low doses of thrombin. In
agreement with previously reported data [34], we found that
cholesterol depletion with methyl-β-cyclodextrin (MβCD) did
not affect maximal platelet aggregation caused by high doses
of thrombin (data not shown). By contrast, Fig. 1a–b showsFig. 1. Lipid rafts mediate the 17β-E2 potentiation of thrombin-induced plate-
let aggregation. Samples of washed platelets suspension, pre-treated (MβCD)
or not (NT) with 20 mM MβCD for 30 min at 37 °C, were stimulated with
0.04 U/ml thrombin (Thr) alone (panels a and b), or in association with 100 nM
17β-E2, (panels c and d). Aggregation traces from a representative experiment
out of 6 performed with platelets obtained from different donors are reported.that MβCD-treated platelets stimulated with low doses of
thrombin were still able to change their shape, but they did
not aggregate at all. As shown in Fig. 1a–c, and as
previously demonstrated [19], 17β-E2 induced a significant
potentiation of platelet aggregation induced by a low dose of
thrombin. However, Fig. 1d shows that 17β-E2 was unable to
potentiate the effect of a low dose of thrombin in MβCD-
treated platelets. These results indicate that the integrity of
membrane lipid rafts is crucial for 17β-E2-dependent signal
transduction in platelets, and suggest a key role for these
microdomains in the 17β-E2-dependent priming of platelet
aggregation.
3.2. Lipid rafts are required for Src kinase activation in
17β-E2-treated platelets
The rapid, non-genomic effects of 17β-E2 in human plate-
lets are mediated by ERβ receptors, which recruit and activate
the tyrosine kinase Src [19]. To investigate the role of mem-
brane lipid rafts in 17β-E2-induced signal transduction
pathway, we analyzed the effect of cholesterol depletion by
MβCD on the hormone-dependent activation of Src. Fig. 2
shows that in untreated platelets 17β-E2 promoted an evident
phosphorylation of the Src kinase, that reached a maximum
within 1 min of incubation and then rapidly decreased to the
basal level. However, no 17β-E2-dependent tyrosine phos-
phorylation of Src was detected in platelets treated with
MβCD. This implies that the integrity of membrane lipid rafts
is essential for the 17β-E2-dependent activation of the tyrosine
kinase Src in platelets.
3.3. ERβ translocates to the lipid rafts upon stimulation
with 17β-E2
We next investigated whether ERβ was resident within the
lipid rafts of the platelet membrane. Recent reports have de-
scribed different experimental protocols as suitable to isolate
lipid rafts from human platelets, using either 0.1% Brij58 or
0.1% Triton X-100 [20,35]. In preliminary experiments, upon
platelet lysis with Brij58, we found that GM1 ganglioside, a
positive marker for membrane lipid rafts, was recovered in less
Fig. 4. ERβ translocates to the lipid rafts upon stimulation of platelets with
17β-E2. Samples of platelet suspension, treated or not with 20 mM MβCD for
30 min at 37 °C, were incubated with vehicle or with 100 nM 17β-E2 for 30 or
60 s, as indicated, and then lysed in ice-cold 0.1% Brij58-containing buffer.
Cell lysates were fractionated as described in Materials and methods. GM1-
containing fractions (raft fractions) and more dense soluble fractions were
combined, proteins were precipitated with TCA, and then analyzed by im-
munoblotting with anti-ERβ specific antibody. The immunoblot analysis shown
in the figure is from a representative experiment out of the 8 performed with
platelets obtained from different donors.
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accordance with Wonerow et al. [36] (data not shown). In
addition, more reproducible results were generally obtained by
using Brij58-lysed platelets, and, therefore, this detergent
was adopted for all the experiments described in this paper.
Fig. 3A shows that GM1 ganglioside was mainly recovered in
the fractions 4 to 7. LAT, a protein resident in membrane lipid
rafts, was detected in the same fractions. By contrast ERK,
known as negative marker of lipid rafts, was found exclu-
sively in the fractions 11 and 12. The treatment of platelets with
MβCD resulted in GM1 ganglioside redistribution throughout
the sucrose gradient, demonstrating that cholesterol is essential
to segregate the GM1 ganglioside in less dense fractions of
platelet membrane (Fig. 3B).
GM1-positive fractions of each sample were pooled as the
lipid raft fraction. Moreover, fractions 11 and 12 were
separately collected as the soluble fraction, while the pellet
was discharged.
The combined fractions were then subjected to protein
precipitation with TCA, and analyzed by immunoblotting
with anti-ERβ specific antibody. A very small amount of
ERβ was detected in the soluble fractions of resting platelets
(Fig. 4). Upon stimulation with 17β-E2, a rapid and transient
translocation of ERβ to the lipid rafts occurred, with a
maximum at 30 s. Interestingly, despite the faintness of the
ERβ bands, a concomitant decrease of ERβ could be detect
in the soluble fractions obtained from the same samples (Fig.
4). Moreover, in MβCD-cholesterol-depleted platelets ERβ
was no longer detected in the lipid raft fractions. Accordingly
with the evidence shown in Fig. 3, we assumed that MβCD
rendered ERβ undetectable by distributing the receptor
overall the fractions. These results indicate that the engage-
ment of ERβ by its specific ligand caused the rapid and
transient recruitment of ERβ to the membrane lipid rafts.Fig. 3. Platelet lysis and recovery of membrane lipid rafts by sucrose den-
sity gradient. Samples of platelet suspension were lysed with ice-cold 0.1%
Brij58-containing buffer and centrifuged in sucrose density gradient as
described in Materials and methods. 12 fractions of equal volumes (1 ml)
were collected and analyzed by dot blot with peroxidase-conjugated-cholera
toxin subunit to identify the fractions containing the GM1 ganglioside and by
immunoblot with anti-LAT and anti-p44/42 ERK antibodies (A). Samples of
platelet suspension treated with 20 mM MβCD for 30 min at 37 °C were
fractionated and analyzed by dot blot with peroxidase-conjugated-cholera toxin
in the same manner (B). The analysis reported in the figure are from a repre-
sentative experiment out of the 4 performed with platelets obtained from dif-
ferent donors.3.4. Lipid rafts mediate the 17β-E2 signaling in
human platelets
We have previously shown that Src, Pyk2 and p85-PI3-K
associated to ERβ upon treatment of human platelets with 17β-
E2 [19]. To further characterize the role of lipid rafts in 17β-E2
signaling, we investigated the presence of these signal
transducers in the lipid rafts isolated from 17β-E2-treated
cells. Samples of resting and 17β-E2-treated platelets were
lysed with Brij58 and fractionated by sucrose gradient cen-
trifugation as described. Aliquots of combined raft and soluble
fractions were analyzed by immunoblotting with antibodies
specific for the Tyr418-phosphorylated form of Src (pSrc-
Tyr418), Src, the Tyr402-phosphorylated form of Pyk2
(pPyk2–Tyr402), Pyk2 and p85-PI3-K. Fig. 5 shows that in
resting platelets the signal transducers considered were un-
equally distributed between raft and soluble fractions. In fact,Fig. 5. Lipid rafts mediate the 17β-E2-dependent signaling in human platelets.
Samples of platelet suspension were treated with vehicle or with 100 nM 17β-E2
for 30 or 60 s, and then lysed in ice-cold 0.1% Brij58-containing buffer. Raft
fractions and soluble fractions obtained as described in Fig. 4 were analyzed by
immunoblotting with antibodies specific to the Tyr418-phosphorylated form of
Src (pSrc-Tyr418), Src, the Tyr402-phosphorylated form of Pyk2 (pPyk2–
Tyr402), Pyk2 and p85-PI3-K. The immunoblot analysis shown in the figure is
from a representative experiment out of the 6 performed with platelets obtained
from different donors.
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membrane lipid rafts of resting cells, Pyk2 was mainly located
in the soluble fractions, and p85-PI3-K seemed to be equally
distributed in raft and soluble fractions. A mild Src kinase
activation was detected already in the rafts of resting cells.
However, upon 17β-E2 platelet stimulation, a consistent in-
crease in Src Tyr418 phosphorylation occurred, which was
paralleled by a concomitant increase of Src associated with the
lipid rafts. As reported by the antibody datasheets, we found
that antibodies to Src and pSrc-Tyr418 recognized at least a
couple of proteins that were presumably two members of the Src
kinase family. We did not identify which members of the Src
kinase family were modulated by 17β-E2, however Fig. 5
shows that they behaved in the same manner with this respect.
Moreover, 17β-E2-dependent Src kinases activation and
translocation to raft fractions were rapid and reversible events,
indicating that they were presumably related to each other.
Besides this, in 17β-E2-stimulated cells a discrete amount
of Pyk2 was recruited to the lipid rafts with a kinetic similar
to that of Src (Fig. 5). However, whilst the 17β-E2-induced
association with the raft fractions and activation of Src seemed
to be concomitant events, the tyrosine-phosphorylation of
Pyk2 persisted up to 60 s of treatment with 17β-E2. More-
over, we found that 17β-E2 did not modulate the p85-PI3-
K distribution within platelet membrane fractions (Fig. 5).
Finally, the integrity of the lipid rafts was found to be cru-
cial for 17β-E2 signaling, as neither Src nor Pyk2 were de-
tected in these microdomains upon MβCD treatment (data
not shown).
4. Discussion
It has been previously shown that estrogen can significantly
potentiate the aggregation induced by low doses of thrombin, by
initiating a rapid and reversible signaling pathway mediated by
ERβ-directed activation of the tyrosine kinases Src and Pyk2
at the level of the plasma membrane [19].
In this work we have demonstrated that membrane lipid
rafts play an important role in these events, as they mediate the
estrogen-dependent outside-in signaling in platelets. The in-
volvement of lipid rafts in estrogen-dependent signaling in these
cells was indicated by studies with the cholesterol-binding agent
MβCD. We found that in platelets in which the integrity of
lipid rafts had been disrupted through cholesterol depletion by
MβCD, treatment with 17β-E2 failed to induce tyrosine phos-
phorylation of Src, and did not cause any potentiation of
thrombin-dependent platelet aggregation. In agreement with
previous works [35], we found that lipid raft integrity was not
required for the aggregation induced by high doses of throm-
bin. Our results imply that membrane lipid rafts exert a specific
and fundamental role in the signaling pathways activated by
estrogens in human platelets.
In human platelets the main estrogen receptor is a
glycosylated form of ERβ that is localized in the membranes
[19,37]. In this work, we have shown that estrogen induced a
rapid but transient translocation of the membrane-associated
ERβ into hydrophobic microdomains of the platelet membrane.The 17β-E2-dependent translocation of ERβ to these
hydrophobic microdomains required the presence of cholesterol
in the membrane, thus it is reasonable to assume that the
hormone drives ERβ to membrane lipid rafts. Although ad-
ditional experiments will be required to completely clarify the
mechanism of this translocation, it is likely that binding of
17β-E2 may cause a conformational change of ERβ promoting
its selective relocation within rafts.
We found that the treatment of platelets with 17β-E2 re-
sulted in the recruitment of the tyrosine kinases Src and Pyk2 to
lipid rafts, which was concomitant with their rapid and
reversible tyrosine-phosphorylation. In agreement with pre-
vious works [38], we have found that at least two members of
the Src kinase family were constitutively associated to the
membrane rafts also in human platelets. However, we have
also provided evidence that estrogens caused an evident
increase of the association of Src proteins with these micro-
domains, and promoted the tyrosine phosphorylation of rafts-
associated Src kinases. In the light of our results it is reasonably
to suppose that 17β-E2-engaged ERβ is responsible for the
recruitment to the rafts of the signal transducers involved in
17β-E2-dependent signaling, in particular Src kinases and
Pyk2. This hypothesis is confirmed by the inhibition of both
Src activation and 17β-E2-dependent translocation of ERβ,
Src and Pyk2 to lipid rafts in MβCD-treated platelets. More-
over, in a previous work, we have shown that in 17β-E2-treated
platelets Src, Pyk2 and PI3-K associated to ERβ to form a
signal molecular complex [19]. However, in contrast to what
was reported for other cells, PI3-K did not play any active role
in 17β-E2-dependent signaling in human platelets. Here we
confirmed and extended these findings, by showing that dis-
tribution of PI3-K between raft and soluble fractions, was not
modulated by 17β-E2.
Noteworthy, ERβ is a membrane protein poorly expressed
in platelets. It can be inferred that lipid rafts may represent a
structural–functional link between the engaged estrogen re-
ceptor and its specific intracellular interactors. Moreover, lipid
rafts could bring some hierarchy to the multitude of signaling
pathways contributing to platelet activation, based on the con-
centration of interactive signaling complexes in well-defined
morphological membrane compartments.
In conclusion, we propose that membrane lipid rafts play a
key role in 17β-E2-dependent signaling in human platelets and
are directly involved in the molecular mechanism by which
estrogen exerts a priming effect on platelet aggregation induced
by low doses of thrombin.
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